David Burrows PDL BioPharma PDLI-Q TOP PICK Feb 27, 2006

Company is developing compounds which won't harm the body but will help. Multi-billion dollar business. He has owned it for about 3 months and continues to buy.

David Burrows

Owned

Unlock Rating

$30.550

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Higher valuation stocks are going to have a tougher time when people are concerned about a slowing economy. This one has been weakening since March. There is no sign of any real bounce on the little bit of recent strength.

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jamie Murray

Murray Wealth Group

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

David Burrows PDL BioPharma PDLI-Q TOP PICK Feb 27, 2006

You might be interested:

PDL BioPharma(PDLI-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals